Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Tirzepatide lowers heart attack and cardiovascular event risk in adults with type 2 diabetes

10

Aug 2026

Tirzepatide lowers heart attack and cardiovascular event risk in adults with type 2 diabetes

In a US cohort of 52,971 adults with type 2 diabetes and established atherosclerotic cardiovascular disease, tirzepatide initiation was associated with a lower one-year risk of major adverse cardiovascular events than sitagliptin. The benefit was driven mainly by lower myocardial infarction and all-cause mortality hazards, although the authors cautioned that mortality findings may be influenced by residual confounding.

Study links better midlife vascular health to nearly 13 more dementia-free years

10

Aug 2026

Study links better midlife vascular health to nearly 13 more dementia-free years

A long-term study of 12,409 adults found that a greater burden of diabetes, hypertension, and current smoking in midlife was associated with substantially fewer years lived free of dementia. Adults with none of these risk factors had about 30.1 dementia-free years from age 55, compared with 17.5 years among those with all three, a difference of nearly 13 years.

Single-dose psilocybin shows promise for treatment-resistant depression in NHS trial

10

Aug 2026

Single-dose psilocybin shows promise for treatment-resistant depression in NHS trial

A single 25-mg dose of psilocybin with psychological support was feasible to deliver within an NHS setting and produced large preliminary reductions in depressive symptoms among adults with treatment-resistant depression. The Phase 2 feasibility trial also found the treatment was generally well tolerated, although functional unblinding and expectancy effects mean larger, longer efficacy studies are needed.

New human genome benchmark captures both parental copies with near-perfect accuracy

10

Aug 2026

New human genome benchmark captures both parental copies with near-perfect accuracy

Researchers created T2T-HG002, a near-perfect diploid human genome benchmark that is free of detectable errors across 99.4% of the genome and captures both maternal and paternal haplotypes. The benchmark expands coverage into previously excluded genomic regions and provides a new framework for evaluating sequencing reads, assemblies, phased variants, and personalized genome inference.

Simple biological age score flags higher cognitive decline risk in older adults

10

Aug 2026

Simple biological age score flags higher cognitive decline risk in older adults

A study of 4,818 middle-aged and older Chinese adults found that higher light BioAge was associated with greater risks of cognitive impairment, episodic memory decline, and reduced mental intactness. The simple measure, based on age, creatinine, glucose, and CRP, added modest predictive information but requires further validation before clinical use.

Simple biological age score flags higher cognitive decline risk in older adults

10

Aug 2026

Simple biological age score flags higher cognitive decline risk in older adults

A study of 4,818 middle-aged and older Chinese adults found that higher light BioAge was associated with greater risks of cognitive impairment, episodic memory decline, and reduced mental intactness. The simple measure, based on age, creatinine, glucose, and CRP, added modest predictive information but requires further validation before clinical use.

Why pulses could play a bigger role in healthy and sustainable diets

9

Aug 2026

Why pulses could play a bigger role in healthy and sustainable diets

A narrative review finds that pulses may support gut and metabolic health through their fiber, protein, phytochemicals, and interactions with the gut microbiota, while offering a lower environmental footprint than many animal protein sources. Human evidence is strongest for selected cardiometabolic outcomes, while many microbiome and fermentation-related benefits remain supported mainly by animal and laboratory studies.

Study finds more than half of mapped US parks lie near toxic chemical-reporting facilities

9

Aug 2026

Study finds more than half of mapped US parks lie near toxic chemical-reporting facilities

A nationwide geospatial analysis of 151,366 publicly accessible parks found that 52.6% lay within two miles of at least one industrial facility reporting toxic chemical management to the EPA, while 17.7% had parkland within two miles of a current or former Superfund site. The study mapped proximity rather than contamination or exposure, highlighting locations where targeted environmental assessment and healthier urban planning may be warranted.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.